Commerzbank Aktiengesellschaft FI Purchases 314 Shares of Waters Corporation $WAT

Commerzbank Aktiengesellschaft FI boosted its stake in Waters Corporation (NYSE:WAT) by 6.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,496 shares of the medical instruments supplier’s stock after purchasing an additional 314 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Waters were worth $1,918,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Olde Wealth Management LLC bought a new stake in shares of Waters during the first quarter valued at about $25,000. Zions Bancorporation National Association UT bought a new stake in shares of Waters during the first quarter valued at about $28,000. IFP Advisors Inc increased its position in shares of Waters by 118.9% during the first quarter. IFP Advisors Inc now owns 81 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 44 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Waters during the first quarter valued at about $41,000. Finally, CX Institutional bought a new stake in shares of Waters during the first quarter valued at about $75,000. 94.01% of the stock is currently owned by institutional investors.

Waters Price Performance

Shares of Waters stock opened at $331.74 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.22 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $19.75 billion, a PE ratio of 29.91, a price-to-earnings-growth ratio of 3.08 and a beta of 1.04. The business’s 50-day moving average price is $299.97 and its 200-day moving average price is $324.19. Waters Corporation has a 12 month low of $275.05 and a 12 month high of $423.56.

Waters (NYSE:WAT) last announced its quarterly earnings data on Thursday, May 19th. The medical instruments supplier reported $2.29 EPS for the quarter. The firm had revenue of $608.55 million for the quarter. Waters had a return on equity of 38.60% and a net margin of 21.71%. Sell-side analysts forecast that Waters Corporation will post 12.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

WAT has been the topic of a number of research analyst reports. UBS Group restated a “neutral” rating on shares of Waters in a research note on Tuesday, July 15th. Wells Fargo & Company decreased their target price on Waters from $330.00 to $315.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 5th. Scotiabank restated a “sector outperform” rating and issued a $465.00 target price on shares of Waters in a research note on Friday, July 11th. Robert W. Baird decreased their target price on Waters from $374.00 to $352.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 16th. Finally, Wall Street Zen lowered Waters from a “buy” rating to a “hold” rating in a research note on Saturday, July 26th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $377.56.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.